2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds MacroGenics (MGNX) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Firm

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

SAN FRANCISCO, Nov. 10, 2019 — Hagens Berman urges MacroGenics (NASDAQ: MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. Only two days remain until the November 12, 2019 lead plaintiff deadline in a securities fraud class action pending against the company.

Class Period: Feb. 6, 2019 – June 3, 2019 Lead Plaintiff Deadline: Nov. 12, 2019 Sign Up: https://www.hbsslaw.com/investor-fraud/mgnx Contact An Attorney Now: [email protected] | 510-725-3000

MacroGenics (MGNX) Securities Class Action:

According to the Complaint, Defendants concealed adverse information obtained during MacroGenics’ clinical trial evaluating Margetuximab, a potential breast cancer treatment. Specifically, as early as October 2018, Defendants knew but omitted to disclose that (1) the progression-free survival (“PFS”) of patients in the trial was negligible, and (2) the overall survival (“OS”) was not statistically significant. The market learned the truth on June 4, 2019, when MacroGenics disclosed the lackluster PFS and OS results. This news drove the price of MGNX shares sharply lower that day.

If you invested in MacroGenics between Feb. 6, 2019 and June 3, 2019 and suffered losses in excess of $50,000 you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case. Contact Hagens Berman immediately to obtain additional information about this case or being a lead plaintiff.

“We are focused on investors’ losses and the extent to which Defendants’ statements may have been misleading,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding MacroGenics should consider their options to help in the investigation or take advantage of the SEC whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].

About Hagens Berman Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact: Reed Kathrein, 510-725-3000

Primary Logo